© 2000 American Heart Association, Inc.
UltraRapid Communication |
Phosphate Regulation of Vascular Smooth Muscle Cell Calcification
From the Departments of Bioengineering (S.J., C.M.G.) and Pathology (C.E.M., C.M.G.), University of Washington, Seattle, Wash; Dentistry (M.D.M) and Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada; and Second Department of Internal Medicine (A.S., Y.N., K.M., H.M.), Osaka City University Medical School, Osaka, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Vascular calcification is a common finding in atherosclerosis and a serious problem in diabetic and uremic patients. Because of the correlation of hyperphosphatemia and vascular calcification, the ability of extracellular inorganic phosphate levels to regulate human aortic smooth muscle cell (HSMC) culture mineralization in vitro was examined. HSMCs cultured in media containing normal physiological levels of inorganic phosphate (1.4 mmol/L) did not mineralize. In contrast, HSMCs cultured in media containing phosphate levels comparable to those seen in hyperphosphatemic individuals (>1.4 mmol/L) showed dose-dependent increases in mineral deposition. Mechanistic studies revealed that elevated phosphate treatment of HSMCs also enhanced the expression of the osteoblastic differentiation markers osteocalcin and Cbfa-1. The effects of elevated phosphate on HSMCs were mediated by a sodium-dependent phosphate cotransporter (NPC), as indicated by the ability of the specific NPC inhibitor phosphonoformic acid, to dose dependently inhibit phosphate-induced calcium deposition as well as osteocalcin and Cbfa-1 gene expression. With the use of polymerase chain reaction and Northern blot analyses, the NPC in HSMCs was identified as Pit-1 (Glvr-1), a member of the novel type III NPCs. These data suggest that elevated phosphate may directly stimulate HSMCs to undergo phenotypic changes that predispose to calcification and offer a novel explanation of the phenomenon of vascular calcification under hyperphosphatemic conditions. The full text of this article is available at http://www.circresaha.org.
Key Words: vascular calcification • hyperphosphatemia • inorganic phosphate • human smooth muscle cell • sodium-dependent phosphate transport • Pit-1 • Cbfa-1
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vascular calcification refers to the deposition of calcium phosphate mineral, most often hydroxyapatite, in cardiovascular tissues including arteries, heart valves, and cardiac muscle. Vascular calcification is often encountered in the development of atherosclerotic intimal lesions and is a common consequence of aging.1 In diabetic patients and individuals with renal failure, vascular calcification contributes to both the morbidity and mortality associated with these diseases.2 For example, vascular calcification is positively correlated with increased risk of myocardial infarction and increased risk of dissection after angioplasty.3 Moreover, calcification is a major cause of failure for both native and tissue prosthetic heart valves, affecting 1% to 2% of the aging population.4
Until recently, vascular calcification was considered to be a passive, degenerative, and end-stage process of vascular disease. However, the observation of matrix vesicles, bone morphogenetic proteins, and noncollagenous bone matrix proteins such as osteopontin, osteonectin, osteocalcin, and matrix Gla protein (MGP) in calcified vascular tissues has challenged this paradigm (see Giachelli5 for review). Similarly, vascular media–derived cell cultures have the capacity to express alkaline phosphatase, osteocalcin, and osteopontin and calcify their extracellular matrix under appropriate conditions.6 7 8 Perhaps the most compelling evidence for active regulation of vascular calcification, however, has come from recent genetic studies in mice. The MGP-null mouse shows extensive calcification of the arterial tree, indicating that MGP, which is constitutively expressed in arterial SMCs, is normally an important inhibitor of vascular calcification.9 In addition, several other mutant mouse strains including the KLOTHO mouse deficient in b-glucosidase,10 the carbonic anhydrase II mutant,11 desmin-null mouse,12 and osteoprotegerin-null mouse13 show enhanced susceptibility to vascular calcification. Finally, structures identical to bone and bone marrow are occasionally found in advanced atherosclerotic lesions, calcified cardiac valves, and Monckeberg’s sclerosis (see Parhami et al14 for review). These findings suggest that vascular calcification is in fact an actively regulated process in which vascular cells may acquire osteoblast-like functions.
Despite its clinical impact and evidence of genetic control, the molecular mechanisms regulating vascular calcification remain obscure. A clue to this process, however, is suggested by several observations linking serum phosphate levels with a tendency toward vascular calcification. First, a high serum phosphate level (hyperphosphatemia, ie, phosphate levels higher than the normal adult range of 1.0 to 1.5 mmol/L) is highly correlated with extent of vascular calcification and vascular disease.15 16 One of the most common causes of hyperphosphatemia is chronic renal failure and subsequent kidney dialysis, in which serum inorganic phosphate (Pi) levels can typically exceed 2 mmol/L.16 17 Vascular calcification observed in these patients is routinely referred to as metastatic calcification because it occurs in the presence of a systemic mineral imbalance. Second, in both experimental animals and children, prosthetic valve calcification is correlated with elevated phosphate levels.18 19 Third, as mentioned above, the KLOTHO mutant mouse develops extensive vascular medial calcification and has twice the serum phosphate levels found in wild-type mice.10 Finally, local disturbances of calcium and phosphate metabolism in atherosclerotic plaques have been suggested to contribute to the development of vascular calcification.20 Thus, it is hypothesized that an important regulator of vascular calcification is the level of Pi.
To test this hypothesis and further clarify the molecular mechanisms regulating vascular calcification, we have characterized the response of human aortic smooth muscle cell (HSMC) cultures to Pi levels. Our findings indicate that Pi directly regulates HSMC calcification through a sodium-dependent phosphate transporter–sensitive mechanism and implicate this mechanism in the development of ectopic calcification in vivo.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Reagents
DMEM (high glucose, 4.5 g/L of glucose) and FBS were purchased from Gibco. cDNAs encoding human osteocalcin and core-binding factor
subunit 1 (Cbfa-1) were gifts from Dr Shioi.
H332PO4,
L-[3H]alanine and
[-32P]dCTP were obtained from New England
Nuclear. Unless otherwise mentioned, all other reagents were obtained
from Sigma.
Human Tissues and Cell Culture
HSMCs were obtained by enzymatic digestion as previously
described.21 Briefly, medial tissues were separated from
segments of human adult or fetal aorta obtained at heart transplant
surgery and autopsy, respectively. For plaque SMCs,
coronary atherectomy–derived tissues were obtained at the time
of surgery. All tissues were obtained from the University of Washington
Medical Center and the University of Washington Central Laboratory for
Human Embryology under the guidelines of the University of Washington
Human Subjects Division. Small pieces of tissue (1 to 2
mm3) were digested overnight in DMEM supplemented
with 165 U/mL collagenase type I, 15 U/mL elastase type
III, and 0.375 mg/mL soybean trypsin inhibitor at 37°C.
Single cell suspensions were placed in 6-well plates and cultured for
several weeks in DMEM supplemented with 20% FCS at 37°C in a
humidified atmosphere containing 5% CO2.
Cultures that formed colonies were collected at confluence and
maintained in growth medium (DMEM containing 15% FBS and 1 mmol/L
sodium pyruvate supplemented with 100 U/mL of penicillin and 100 mg/mL
of streptomycin; final Pi concentration=1.4
mmol/L). Purity of cultures was assessed by positive
immunostaining for -SM actin and calponin and
absence of von Willebrand factor staining as previously
described.21 Human adult and fetal aortic medial and
coronary plaque primary cells were used to passage 8. Fetal and
adult HSMC cultures immortalized using the HPV-E6E7 as previously
described were used between passages 20 and 30.22 Human
fetal SMCs were used for most studies unless otherwise indicated.
Induction of Calcification
HSMCs were routinely subcultured in growth medium. At
confluence, the cells were switched to calcification medium (DMEM
containing 15% FBS and 1 mmol/L sodium pyruvate in the presence
of 2 mmol/L Pi (unless otherwise stated)
supplemented with 100 U/mL of penicillin and 100 µg/mL of
streptomycin) for up to 14 days. Both growth medium and calcification
medium contained 1.8 mmol/L calcium. The medium was replaced with
fresh medium every 2 days. For time-course experiments, the first day
of culture in calcification medium was defined as day 0.
Quantification of Calcium Deposition
Cells were decalcified with 0.6 N HCl for 24 hours. The calcium
content of HCl supernatants was determined
colorimetrically by the o-cresolphthalein
complexone method (Calcium kit; Sigma) as previously
described.23 After decalcification, the cells were
washed three times with PBS and solubilized with 0.1 N NaOH/0.1% SDS.
The protein content was measured with a BCA protein assay kit (Pierce).
The calcium content of the cell layer was normalized to protein
content.
Cytochemical and Ultrastructural Analysis
Cell cultures were fixed either in pure ethanol for mineral
analyses or in an aldehyde mixture for several hours followed
by dehydration and embedding in LR White acrylic resin (Marivac). For
morphological observations, sections were cut on a Reichert
ultramicrotome and placed onto glass slides or electron microscopy
grids. Mineral deposition was assessed at the light microscopic level
by von Kossa staining (30 minutes, 5% silver nitrate) and sections
were counterstained with toluidine blue. Transmission electron
microscopy and electron diffraction were also performed on selected
areas of the cultures.
Phosphate and Alanine Transport Assays
Transport studies were performed at 37°C in EBSS with 15
mmol/L HEPES adjusted to pH 7.4. The composition of this solution was
(in mmol/L) sodium or choline 143, potassium 5.36, magnesium 0.8,
calcium 1.8, and chloride 125. Transport was initiated by adding 1 mL
of the above medium containing the labeled substrate
H332PO4 (1
µCi/mL) to HSMCs at confluence.24 For alanine transport,
the EBSS solution contained 0.1 mmol/L
L-[3H]alanine (1 µCi/mL). After
various incubation times, the uptake was stopped by washing the cell
monolayer three times with ice-cold stop solution (EBSS with 15
mmol/L HEPES adjusted to pH 7.4) at 4°C without
Pi. The cells were solubilized with 1 mL of 0.1 N
NaOH/0.1% SDS, and the radioactivity of 100-µL aliquots was counted
by standard liquid scintillation techniques. Protein concentrations
were determined with a BCA protein assay kit (Pierce), and the data
were normalized by the protein content of the cell layer.
Reverse Transcription–Polymerase Chain Reaction (RT-PCR) and
Preparation of cDNA Probes
RT-PCR was performed as previously described.23
Human type III sodium-dependent phosphate cotransporter (NPC) Pit-1
(Glvr-1) cDNA was amplified using the following primer sequences:
forward: 5'-TACCATCCTCATCTCGGTGG-3', reverse:
5'-TGACGG-CTTGACTGAACTGG-3'. A 409-bp fragment was obtained
by reverse transcription of an mRNA from human fetal SMCs, followed by
the polymerase chain reaction and subcloning into the TA cloning vector
(Invitrogen). The identity of the cDNA insert as Pit-1 corresponding to
positions 1060 to 1469 of the coding region25 was
confirmed by DNA sequence analysis (data not shown).
RNA Isolation and Northern Blot Analysis
Total RNA was isolated from HSMCs by extraction with Trizol as
suggested by the manufacturer (Gibco). Total RNA was isolated from
fetal aortic tissue by extraction with acid guanidium
thiocyanate-phenol-chloroform. Total RNA was electrophoresed on 1%
agarose gels containing formaldehyde and transferred to a nylon filter
(Zeta-Probe GT, Bio-Rad). Blots were prehybridized at 42°C for 1 hour
in a buffer containing 50% formamide, 0.75 mol/L NaCl, 50 mmol/L
Tris-HCl (pH 7.5), 1% SDS, 10% dextran sulfate, 20 µg/mL denatured
salmon sperm DNA, and 1x Denhardt’s solution and then hybridized at
42°C for 24 hours with cDNA probe for human Pit-1, human osteocalcin,
and human Cbfa-1, which were labeled with
[-32P]dCTP (3000 Ci/mL; New England Nuclear)
with use of a random priming method (Megaprime cDNA labeling system;
Amersham). Blots were washed and autoradiographed with x-ray film at
-70°C. The amounts of RNA were quantified by densitometric scanning
and normalized by comparison with GAPDH.
Statistics
Data were analyzed for statistical significance by ANOVA
with post hoc Scheffé’s F analysis, unless otherwise
stated. These analyses were performed with the assistance of a
computer program (StatView version 4.11, Abacus Concepts,
Berkeley, Calif).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Pi Induces Calcium Deposition in HSMCs
Vascular calcification occurs frequently in individuals with hyperphosphatemia whose serum phosphate levels typically exceed 1.4 mmol/L.15 16 17 To develop an in vitro model for human vascular calcification, the effect of Pi on calcification of HSMC cultures was examined. In media containing normal serum phosphate levels (Pi=1.4 mmol/L), HSMCs accumulated very little calcium mineral (Figure 1A
). In contrast, in the presence of
2 mmol/L Pi, calcium deposition dramatically
increased in a time-dependent manner (on day 9, calcified HSMC cultures
versus uncalcified control: 210.3±2.4 versus 15.1±2.4 µg/mg
protein, mean±SEM, n=3) (Figure 1A). Furthermore, the effect of
Pi was dose-dependent (on day 6, calcified HSMCs
[in the presence of 2 mmol/L PI] versus
uncalcified HSMCs [in the presence of 1.4 mmol/L
PI]: 142.9±13.3 versus 37.1±1.2 µg/mg
protein, mean±SEM, n=3) (Figure 1B). Induction of calcification
by elevated Pi appeared to be a general feature
of HSMCs because primary cells derived from different sources (human
adult and fetal aortic and coronary plaque), as well as
immortalized derivates of these cells, showed similar behavior (Figure 1C). In addition, bovine aortic valve interstitial
cells, but not NIH3T3 cells or bovine aortic
endothelial cells, underwent matrix calcification under
similar elevated phosphate conditions (data not shown). No spontaneous
deposition of calcium mineral occurred in calcification media or in
media supplemented with up to 10 mmol/L Pi
indicating that cells or cell-derived matrix was necessary for
mineralization of HSMC cultures. These results indicate that HSMC
cultures are susceptible to calcification when cultured in media
containing Pi concentrations typically observed
in patients with hyperphosphatemia.
|
). Two mmol/L
Pi and 1.4 mmol/L Pi indicate
concentration of Pi in the medium. The calcium contents
were measured at the indicated times by
o-cresolphthalein complexone method, normalized by
cellular protein content, and are presented as mean±SEM. The
differences compared with uncalcified control at the same time were
statistically significant (*P<0.01, Scheffé’s
test). B, HFSMCs were cultured in medium containing the indicated
concentration of Pi for 6 days. The calcium contents were
measured at the indicated times by o-cresolphthalein
complexone method, normalized by cellular protein content, and are
presented as mean±SEM. The differences compared with
uncalcified control (1.4 mmol/L Pi) were statistically
significant (*P<0.01, Scheffé’s test). C, Effect
of 2 mmol/L Pi on various isolates of primary and
immortalized HSMCs. The cells were cultured in calcification medium or
growth medium for 6 days. The calcium contents were measured at the
indicated times by o-cresolphthalein complexone method,
normalized by cellular protein content, and are presented as
mean±SEM. The differences compared with uncalcified control of each
cells were statistically significant (*P<0.01,
Scheffé’s test). The (+) and (-) indicate the presence and
absence of calcification medium (Calc.M), respectively.
Morphology of HSMC Calcification
HSMC cultures grown in growth media showed areas of monolayer and
multilayered growth typical of cultured smooth muscle (Figure 2A). After culturing HSMCs in
calcification medium for 10 days, granular deposits developed
throughout the cell culture, whereas in the control culture, no
deposits were found during the culture period. The deposits were
identified as phosphate-containing mineral by von Kossa staining and
light microscopy (Figure 2B). Discrete, black-stained areas were
diffusely scattered throughout the cell layer, predominantly in the
extracellular regions, with greatest accumulation at sites of cell
multilayering. Transmission electron microscopy and selected area
electron diffraction of specific sites within the calcified cultures
(data not shown) confirmed the presence of an apatitic mineral phase,
calcified collagen fibers, and matrix vesicles—observations
essentially identical to those previously described for calcifying
bovine SMC cultures.8
|
A Functional NPC Is Required for HSMC Culture
Calcification
To examine the mechanism by which phosphate levels might control
matrix mineralization, we examined phosphate transport in HSMCs. In the
presence of sodium chloride, phosphate uptake was increased in a
time-dependent manner (Figure 3A).
Transport was abolished when sodium ions were replaced with choline
ions in the media. Maximal phosphate accumulation was achieved after
120 minutes (at 120 minutes, sodium chloride versus choline chloride
was 12.24±0.27 versus 0.36±0.06 nmol/mg protein, mean±SEM, n=3)
(Figure 3A). We next examined the relationship between
extracellular phosphate concentration and intracellular phosphate
uptake in HSMC cultures. When the concentration of phosphate in the
medium was increased, phosphate uptake was dose dependently elevated
(in the presence of 3.0 mmol/L Pi versus
0.1 mmol/L Pi: 28.23±0.63 versus 0.64±0.20
nmol/mg protein, mean±SEM, n=3) (Figure 3B). Three
features—time dependence, sodium dependence, and phosphate gradient
dependence—are consistent with the presence of an NPC in
HSMCs.
|
To determine whether NPC activity was required for HSMC culture
calcification, phosphonoformic acid (PFA), a specific, competitive
inhibitor of NPCs, was used.26 As shown in
Figure 4A, PFA time dependently inhibited
sodium-dependent phosphate uptake in HSMCs (at 90 minutes, vehicle
versus 1.0 mmol/L PFA: 12.46±0.41 versus 3.31±0.33 nmol/mg
protein, mean±SEM, n=3) (Figure 4A). Moreover, in the presence
of increasing concentrations of PFA, phosphate uptake was
dose-dependently decreased (vehicle versus 1.0 mmol/L PFA:
12.18±0.861 versus 3.07±0.15 nmol/mg protein, mean±SEM n=3) (Figure 4B). The effect of PFA on HSMC calcification was then
determined. Increasing concentrations of PFA, dose dependently
inhibited HSMC calcium deposition (calcified control [vehicle-treated
cells] versus 2.0 mmol/L PFA: 165.4±2.8 versus 39.8±1.5 µg/mg
protein, mean±SEM, n=3) (Figure 4C). In addition, arsenate, a
second inhibitor of NPC function, also completely inhibited
both Pi uptake and mineralization in HSMC
cultures (data not shown). Together, these data strongly suggest that
an NPC transport system was necessary for mineral deposition in
cultured HSMCs.
|
Phosphate Induces and PFA Blocks Bone Specific Gene Expression
in HSMCs
To further address the mechanism by which phosphate induces HSMC
calcification, we examined levels of osteoblast-specific genes that
have previously been shown to both mark the osteoblast lineage and
regulate bone formation.27 As shown in Figure 5, levels of osteocalcin and Cbfa-1 mRNA
were strongly induced under elevated phosphate conditions. Furthermore,
PFA dose dependently inhibited phosphate-induced expression of these
genes (Figures 5A and 5B). PFA did not affect
calcification or gene expression in HSMCs cultured in 1.4 mmol/L
phosphate (data not shown).
|
HSMC Cultures and Human Arterial Tissues Contain the
Type III NPC Pit-1 (Glvr-1)
Three families of NPCs have been reported to date. The type I
family consists of a single species (NaPi-1),
which has thus far been found only in rabbit kidney.28 The
type II family consists of six species homologues,
NaPi 2 to 7, that are expressed predominantly in
renal epithelial tissues.29 30 31 32 33 The type III family is the
most recently identified and consists of two members, Pit-1 (also
called Glvr-1) and Pit-2 (also called Ram-1).34 To
determine which NPC was potentially involved in HSMC phosphate uptake,
we used RT-PCR with specific primers in an attempt to amplify NPC cDNAs
that have previously been identified in human tissues. As shown in
Figure 6A, a 409-bp band using specific
primers of Pit-1 was obtained from mRNA derived from fetal HSMCs as
well as fetal human aorta, nondiseased human adult coronary,
and diseased human coronary. Sequence analysis of the
409-bp cDNA fragment amplified using the human Pit-1 primers confirmed
the identity as human Pit-1 (data not shown). No bands were obtained
when primers for NaPi-3 (the human type II NPC
family homologue) or Pit-2 were used in RT-PCR from these same tissues
(data not shown).
|
Using the 409-bp human Pit-1 fragment as a probe, we confirmed the
expression of Pit-1 in the various HSMC isolates used in our studies by
Northern blot analysis (Figure 6B
). An mRNA band of 3.7
kb was observed in all HSMCs tested, and this is consistent
with the size reported for Pit-1 mRNA transcripts in
osteoblasts.35 A similarly sized Pit-1 mRNA band was also
observed in mRNA derived from human fetal aorta (Figure 6C),
confirming the RT-PCR data in Figure 6A. Whereas Cbfa-1 and
osteocalcin levels were upregulated after treatment of HSMCs
with 2 mmol/L Pi for 24 hours (Figures 5A and 5B), Pit-1 mRNA levels remained unchanged (data not
shown). These data identify Pit-1 as a major NPC constitutively
present in HSMCs in vitro and in vivo.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The role of Pi in vascular SMC mineralization was investigated using an in vitro model system that was shown to mimic many of the features seen in human metastatic vascular calcification in vivo. We found that HSMCs cultured in media containing normal serum phosphate levels do not mineralize. In contrast, HSMCs treated with media containing phosphate levels comparable to those seen in patients with hyperphosphatemia accumulated significant levels of apatitic mineral in the their matrices. HSMCs were found to contain a functional sodium-dependent phosphate uptake system and mRNA for the type III NPC Pit-1 (Glvr-1). Function of this transporter appeared to be critical for mineralization of HSMC cultures given that PFA significantly inhibited calcium deposition and gene expression of osteoblastic differentiation markers osteocalcin and Cbfa-1 in a dose-dependent manner. These data strongly support the hypothesis that SMCs are induced to secrete a matrix capable of mineralization in response to elevated phosphate levels, and that this process is dependent on NPC function.
In this study, Pi levels regulated the propensity of HSMC cultures to calcify. Pi increased HSMC calcification in a time- and dose-dependent manner, and mineralization induced by Pi was similar to that observed in other culture systems8 and calcified vascular tissues in vivo.36 37 In patients with chronic renal failure treated by hemodialysis, hyperphosphatemia is commonly associated with widespread vascular calcification.38 In fact, recent studies indicate a striking association of serum phosphorus levels with mortality risk in chronic hemodialysis patients,16 39 40 probably a result of the increased calcinosis, calciphylaxis, and secondary hyperparathyroidism typically observed in these patients. When combined with the data from our studies, these observations support the concept that Pi levels may directly regulate vascular calcification. Interestingly, Pi has also been recently implicated in the direct regulation of the parathyroid gland secretion of parathyroid hormone, which is also elevated in individuals with uremia.41 Notably, Pi has been implicated in the regulation of chondrocyte and osteoblast activity.42 However, elevated Pi is clearly not the only stimulus for vascular cell calcification, because pericytes43 and calcifying vascular cells6 apparently do not require supplemental phosphate for mineralization in culture.
To determine how HSMCs might sense elevated phosphate levels, we examined phosphate uptake by these cells. Our data suggest that HSMCs sense Pi levels, at least in part, through an NPC. Three types of NPCs have been identified and are grouped according to homology.44 Type I NPC includes NaPi-1, which is found exclusively in the kidney of rabbits.28 Six members comprise the type II NPC family, including the species homologues NaPi-2, -3, -4, -5, -6, and -7, and these also appear to be predominantly expressed in renal and gut epithelium in many species and are most likely important in the phosphate reabsorption function of these tissues.29 30 31 32 33 Most recently, the type III NPC system was identified and found to be expressed in heart, kidney, bone, and liver. This family includes NPCs that act as receptors for gibbon ape leukemia virus (Glvr-1; Pit-1) and amphotropic murine retrovirus (Ram-1; Pit-2).34 Of these known NPCs, only Pit-1 was identified in our HSMCs as well as in human fetal aorta. This is the first description of an NPC of any type in vascular SMCs. However, definitive proof of Pit-1 as the NPC involved in mediating matrix mineralization in response to elevated phosphate in HSMCs awaits development of a specific Pit-1 inhibitor.
How might elevated phosphate and NPC activity induce HSMC-mediated mineralization? We speculate that under conditions of high extracellular phosphate or enhanced cellular NPC levels, intracellular levels of Pi are increased via the action of Pit-1. This may lead to mechanisms initiating promineralizing metabolic processes within the cell. One of these mechanisms may be increased elaboration of an extracellular matrix that is prone to mineralize. In support of this idea, we found that elevated phosphate levels stimulated expression of both Cbfa-1 and its downstream transcriptional target, osteocalcin, in HSMCs. Similarly, elevated phosphate level was previously shown to induce osteopontin expression in bovine aortic SMCs.7 Osteocalcin and osteopontin are major noncollagenous proteins found in bone matrix and are believed to regulate mineralization (see Giachelli et al45 for review). Cbfa-1 is an osteoblast-specific transcription factor required for osteoblast differentiation, bone matrix gene expression, and, consequently, bone mineralization.46 Cbfa-1 has been previously shown to directly regulate the expression of the major components of bone matrix including collagen type I, osteocalcin, and osteopontin.27 Thus, it is likely that phosphate-signaled increases in Cbfa-1 gene expression in HSMCs leads to enhanced transcription and secretion of an osteoid-like extracellular matrix that contributes to enhanced calcification under hyperphosphatemic conditions. Finally, it is also possible that Pi loading of matrix vesicles released by the mineralizing HSMCs is involved in the calcification process, considering that NPCs have been found in these structures in chondrocytes.47 Accumulation of phosphate in these vesicles, together with the activity of membrane-associated alkaline phosphatase, is thought to play an important role in the initial mineralization of bones and teeth, and matrix vesicles have also been found in calcified vascular tissues in vivo.48
In conclusion, these findings support the hypothesis that extracellular phosphate directly regulates the ability of vascular SMCs to initiate matrix mineralization. Phosphate uptake by an NPC, potentially Pit-1, leads to increased expression of Cbfa-1, a bone-specific transcription factor, and subsequent elaboration of a promineralizing matrix that contains osteopontin and osteocalcin. These findings offer a novel mechanism for explaining metastatic calcification and may lead to new therapeutics aimed at reducing or preventing ectopic calcification.
|
Acknowledgments |
|---|
These studies were supported by NIH grant 1R01 HL62329. Dr Giachelli is an Established Investigator of the American Heart Association. Dr Shioi is a recipient of the Lilly Fellowship Program for Bone and Mineral Research (Eli Lilly Japan and the Japan Osteoporosis Foundation). Dr McKee is a Scholar of the Fonds de la Recherche en Santé du Québec and a member of the Medical Research Council of Canada group in Periodontal Physiology.
|
Footnotes |
|---|
Reprint requests to Cecilia M. Giachelli, PhD, Associate Professor, Bioengineering Department, Box 351720, University of Washington, Bagley Hall, Room 479, Seattle, WA 98195.
Received August 7, 2000; revision received August 31, 2000; accepted September 8, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Blumenthal HT, Lansing AI, Wheeler PA. Calcification of the media of the human aorta and its relationship to intimal arteriosclerosis, aging and disease. Am J Pathol. 1944;20:665–687.
2. Frink RJ, Achor RW, Brown AJ, Kincaid OW, Brandenburg RO. Significance of calcification of the coronary arteries. Am J Cardiol. 1970;26:241–247.[Medline] [Order article via Infotrieve]
3.
Fitzgerald PJ, Ports TA, Yock PG. Contribution of
localized calcium deposits to dissection after angioplasty: an
observational study using intravascular ultrasound.
Circulation. 1992;86:64–70.
4. Loecker TH, Schwartz RS, Cotta CW, Hickman JJ. Fluoroscopic coronary artery calcification and associated coronary disease in asymptomatic young men. J Am Coll Cardiol. 1992;19:1167–1172.[Abstract]
5.
Giachelli CM. Ectopic calcification: gathering hard
facts about soft tissue mineralization. Am J Pathol. 1999;154:671–675.
6. Watson KE, Bostrom K, Rvindranath R, Lam T, Norton B, Demer LL. TGF-ß1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 1994;93:2106–2113.
7.
Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii
H. ß-Glycerophosphate accelerates calcification in cultured
bovine vascular smooth muscle cells. Arterioscler Thromb Vasc
Biol. 1995;15:2003–2009.
8.
Wada T, McKee MD, Steitz S, Giachelli CM.
Calcification of vascular smooth muscle cell cultures: inhibition by
osteopontin. Circ Res. 1999;84:166–178.
9. Luo G, Ducy P, McKee MD, Pinero GJ, Loyerm E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.[Medline] [Order article via Infotrieve]
10. Kuro OM, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki IT, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.[Medline] [Order article via Infotrieve]
11. Spicer SS, Lewis SE, Tashian RE, Schulte BA. Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification. Am J Pathol. 1989;134:947–954.[Abstract]
12. Thornell LE, Carlsson L, Li L, Mericskay M, Paulin D. Null mutation in the desmin gene gives rise to a cardiomyopathy. J Mol Cell Cardiol. 1997;29:2107–2124.[Medline] [Order article via Infotrieve]
13.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J,
Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS.
Osteoprotegerin-deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev. 1998;12:1260–1268.
14. Parhami F, Bostrom K, Watson K, Demer LL. Role of molecular regulation in vascular calcification. J Atheroscler Thromb. 1996;3:90–94.[Medline] [Order article via Infotrieve]
15. Alfrey AC, Ibels LS. Role of phosphate and pyrophosphate in soft tissue calcification. Adv Exp Med Biol. 1978;103:187–193.[Medline] [Order article via Infotrieve]
16. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1236–1237.
17. Winchester JF, Rotellar C, Goggins M, Robino D, Rakowski TA, Argy WP. Calcium and phosphate balance in dialysis patients. Kidney Int Suppl. 1993;41:S174–S178.[Medline] [Order article via Infotrieve]
18. Levy RJ, Qu X, Underwood T, Trachy J, Schoen FJ. Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. J Biomed Mater Res. 1995;29:217–226.[Medline] [Order article via Infotrieve]
19. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol. 1983;113:143–155.[Abstract]
20. Fleckenstein-Grun G, Fleckenstein A. Calcium, a neglected key factor in arteriosclerosis: the pathogenic role of arterial calcium overload and its prevention by calcium antagonists. Ann Med. 1991;23:589–599.[Medline] [Order article via Infotrieve]
21.
Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA,
Schwartz SM, Giachelli CM. The adhesive and migratory effects of
osteopontin are mediated via distinct cell surface integrins. Role
of vß3 in smooth
muscle cell migration to osteopontin in vitro. J Clin
Invest. 1995;95:713–724.
22.
Perez RN, Halbert CL, Smith PP, Benditt EP, McDougall
JK. Immortalization of primary human smooth muscle cells. Proc
Natl Acad Sci U S A. 1992;89:1224–1228.
23.
Jono S, Nishizawa Y, Shioi A, Morii H. Parathyroid
hormone-related peptide as a local regulator of vascular calcification:
its inhibitory action on in vitro calcification by bovine
vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:1135–1142.
24. Caverzasio J, Selz T, Bonjour JP. Characteristics of phosphate transport in osteoblastlike cells. Calcif Tissue Int. 1988;43:83–87.[Medline] [Order article via Infotrieve]
25. O’Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, Dunn KJ, Sass D, Vitek SM, Robins T. Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ. 1990;1:119–127.[Abstract]
26. Loghman AM. Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport. Gen Pharmacol. 1996;27:305–312.[Medline] [Order article via Infotrieve]
27. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–754.[Medline] [Order article via Infotrieve]
28.
Werner A, Moore ML, Mantei N, Biber J, Semenza G, Murer
H. Cloning and expression of cDNA for a Na/Pi
cotransport system of kidney cortex. Proc Natl Acad Sci
U S A. 1991;88:9608–9612.
29.
Sorribas V, Markovich D, Hayes G, Stange G, Forgo J,
Biber J, Murer H,. Cloning of a Na/Pi
cotransporter from opossum kidney cells. J Biol Chem. 1994;269:6615–6621.
30.
Werner A, Murer H, Kinne RK. Cloning and expression of
a renal Na-Pi cotransport system from flounder.
Am J Physiol. 1994;267:F311–F317.
31.
Verri T, Markovich D, Perego C, Norbis F, Stange G,
Sorribas V, Biber J, Murer H. Cloning of a rabbit renal
Na-Pi cotransporter, which is regulated by
dietary phosphate. Am J Physiol. 1995;268:F626–F633.
32. Collins JF, Ghishan FK. Molecular cloning, functional expression, tissue distribution, and in situ hybridization of the renal sodium phosphate (Na+/Pi) transporter in the control and hypophosphatemic mouse. FASEB J. 1994;8:862–868.[Abstract]
33. Hartmann CM, Wagner CA, Busch AE, Markovich D, Biber J, Lang F, Murer H. Transport characteristics of a murine renal Na/Pi-cotransporter. Pflugers Arch. 1995;430:830–836.[Medline] [Order article via Infotrieve]
34. Kavanaugh MP, Kabat D. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int. 1996;49:959–963.[Medline] [Order article via Infotrieve]
35.
Palmer G, Bonjour JP, Caverzasio J. Expression of a
newly identified phosphate transporter/retrovirus receptor in human
SaOS-2 osteoblast-like cells and its regulation by insulin-like growth
factor I. Endocrinology. 1997;138:5202–5209.
36.
O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson
JB, Schwartz SM, Giachelli CM. Osteopontin is synthesized by
macrophage, smooth muscle, and endothelial
cells in primary and restenotic human coronary
atherosclerotic plaques. Arterioscler Thromb. 1994;14:1648–1656.
37. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597–1604.
38. Sarkozi L, Szabo A. Effect of hemodialysis on the distribution of phosphates in blood. Clin Physiol Biochem. 1994;1989:7:184–188.
39. Block GA, Hulbert ST, Levin NW, Port FK. Association of serum phosphorus and calciumxphosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–617.[Medline] [Order article via Infotrieve]
40.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider
D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB.
Coronary-artery calcification in young adults with end-stage
renal disease who are undergoing dialysis. N Engl J
Med. 2000;342:1478–1483.
41. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia NS, Torres A, Rodriguez M. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996;11:970–976.[Medline] [Order article via Infotrieve]
42. Bellows CG, Aubin JE, Heersche JN. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner. 1991;14:27–40.[Medline] [Order article via Infotrieve]
43. Schor AM, Canfield AE, Sutton AB, Arciniegas E, Allen TD. Pericyte differentiation. Clin Orthop. 1995;313:81–91.
44. Murer H, Biber J. Renal sodium-phosphate cotransport. Curr Opin Nephrol Hypertens. 1994;3:504–510.[Medline] [Order article via Infotrieve]
45. Giachelli CM, Steitz S, Jono S. Potential roles of bone matrix proteins in vascular calcification. Clin Calcium. 1999;9:20–27.
46. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89:765–771.[Medline] [Order article via Infotrieve]
47.
Montessuit CJ, Caverzasio JT, Bonjour JP.
Characterization of a Pi transport system in
cartilage matrix vesicles. Potential role in the calcification process.
J Biol Chem. 1991;266:17791–17797.
48. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc. 1976;35:156–162.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. Mathew, K. S. Tustison, T. Sugatani, L. R. Chaudhary, L. Rifas, and K. A. Hruska The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1092 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Orita, H. Yamamoto, N. Kohno, M. Sugihara, H. Honda, S. Kawamata, S. Mito, N. N. Soe, and M. Yoshizumi Role of Osteoprotegerin in Arterial Calcification: Development of New Animal Model Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2058 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mathew, R. J. Lund, F. Strebeck, K. S. Tustison, T. Geurs, and K. A. Hruska Reversal of the Adynamic Bone Disorder and Decreased Vascular Calcification in Chronic Kidney Disease by Sevelamer Carbonate Therapy J. Am. Soc. Nephrol., January 1, 2007; 18(1): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Qunibi Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S95 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Speer, Y.-C. Chien, M. Quan, H.-Y. Yang, H. Vali, M. D. McKee, and C. M. Giachelli Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro Cardiovasc Res, May 1, 2005; 66(2): 324 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Davies, Richard. J. Lund, S. Mathew, and K. A. Hruska Low Turnover Osteodystrophy and Vascular Calcification Are Amenable to Skeletal Anabolism in an Animal Model of Chronic Kidney Disease and the Metabolic Syndrome J. Am. Soc. Nephrol., April 1, 2005; 16(4): 917 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kurihara, Y. Tsuruta, and T. Akizawa Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial Nephrol. Dial. Transplant., February 1, 2005; 20(2): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bottger and L. Pedersen Two Highly Conserved Glutamate Residues Critical for Type III Sodium-dependent Phosphate Transport Revealed by Uncoupling Transport Function from Retroviral Receptor Function J. Biol. Chem., November 1, 2002; 277(45): 42741 - 42747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Speer, M. D. McKee, R. E. Guldberg, L. Liaw, H.-Y. Yang, E. Tung, G. Karsenty, and C. M. Giachelli Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein-deficient Mice: Evidence for Osteopontin as an Inducible Inhibitor of Vascular Calcification In Vivo J. Exp. Med., October 21, 2002; 196(8): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cozzolino, A. S. Dusso, H. Liapis, J. Finch, Y. Lu, S. K. Burke, and E. Slatopolsky The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2299 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke and S. G. Rostand Progression of vascular calcification in uraemic patients: can it be stopped? Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1365 - 1368. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. DOHERTY, H. UZUI, L. A. FITZPATRICK, P. V. TRIPATHI, C. R. DUNSTAN, K. ASOTRA, and T. B. RAJAVASHISTH Rationale for the role of osteoclast-like cells in arterial calcification FASEB J, April 1, 2002; 16(6): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||